NUVL vs. BGNE, GMAB, VTRS, MRNA, ITCI, SMMT, RDY, CTLT, SRPT, and QGEN
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Moderna (MRNA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs.
Nuvalent (NASDAQ:NUVL) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Nuvalent has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
97.3% of Nuvalent shares are held by institutional investors. Comparatively, 48.5% of BeiGene shares are held by institutional investors. 12.5% of Nuvalent shares are held by insiders. Comparatively, 7.4% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Nuvalent has a net margin of 0.00% compared to BeiGene's net margin of -25.94%. BeiGene's return on equity of -25.12% beat Nuvalent's return on equity.
BeiGene received 504 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.18% of users gave Nuvalent an outperform vote while only 69.07% of users gave BeiGene an outperform vote.
Nuvalent has higher earnings, but lower revenue than BeiGene. Nuvalent is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuvalent had 13 more articles in the media than BeiGene. MarketBeat recorded 16 mentions for Nuvalent and 3 mentions for BeiGene. Nuvalent's average media sentiment score of 0.42 beat BeiGene's score of 0.41 indicating that Nuvalent is being referred to more favorably in the media.
Nuvalent currently has a consensus target price of $112.36, indicating a potential upside of 48.16%. BeiGene has a consensus target price of $253.69, indicating a potential upside of 0.00%. Given Nuvalent's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuvalent is more favorable than BeiGene.
Summary
Nuvalent beats BeiGene on 14 of the 18 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 1/20/2025 by MarketBeat.com Staff
